Pritchard-Jones, K, Bergeron, C, de Camargo, B, van den Heuvel-Eibrink, M M, Acha, T, Godzinski, J, Oldenburger, F, Boccon-Gibod, L, Leuschner, I, Vujanic, G, Sandstedt, B, de Kraker, J, van Tinteren, H, Graf, N & SIOP Renal Tumours Study Group 2015, ' Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001) : an open-label, non-inferiority, randomised controlled trial ', Lancet, vol. 386, no. 9999, pp. 1156-1164 . https://doi.org/10.1016/S0140-6736(14)62395-3 Lancet, 386(9999), 1156-1164. Elsevier Limited The Lancet, Vol. 386, No 9999 (2015) pp. 1156-64